Radiotherapy (RT) is known to reduce the rate of disease recurrence following breast-conserving surgery in patients with breast cancer, but also entails irradiation of the heart, which can lead to cardiotoxicity and vascular injury, specifically through sustained inflammation. During the last decades, RT advancements have been made in limiting the heart dose and the link between RT and long-term cardiovascular risk is less clear, with some older studies highlighting a dose-dependent increase in the subsequent rate of ischaemic heart disease, while more recent studies showed no evidence for increased cardiac mortality among women treated with RT. We sought to explore the evolution of coronary inflammation and residual inflammatory risk 2 years after RT in women with breast cancer.